



January 30, 2020

Eli Lilly Canada Inc.

P.O. Box 73, Exchange Tower
130 King Street West, Suite 900
Toronto, Ontario M5X 1B1
1.416.694.3221 | 1.800.268.4446
www.lilly.ca

Discontinuation and shortage of Effient® (prasugrel) in Canada

Dear Healthcare Practitioner,

Lilly and Daiichi Sankyo recently agreed to terminate our licensing agreement for Effient. For their part, Daiichi Sankyo made the decision to stop commercializing Effient in Canada.

In light of these circumstances, we contacted healthcare practitioners in December, to request that they not start any new patients on Effient, and that they consider transitioning their existing patients to new therapies.

As posted on www.drugshortagescanada.ca, we are now experiencing an actual shortage. We are no longer shipping complete orders, and Canada's supply will not be replenished after January 31, 2020.

As such, please do not start any new patients on Effient.

Please transition your current Effient patients to an alternative therapy as deemed medically appropriate.

Medical necessity may prevent doctors from transitioning a very small number of your current Effient patients. Medical necessity for existing Effient patients includes:

- Patients on potent inhibitors or inducers of CYP3A4 who are at risk of thrombi formation and consequently, stroke and/or MI in the first year after PCI.
- Patients that develop thrombi or are unresponsive to ticagrelor or clopidogrel.
- Patients who cannot be switched to ticagrelor and who are on inhibitors of CYP2C19.
- Patients who are intolerant to the adverse events of ticagrelor such as dyspnea and ventricular pauses and who cannot be switched to clopidogrel.
- Patients who experience a hypersensitivity reaction to ticagrelor and who cannot be switched to clopidogrel.
- Patients who are allergic to ticagrelor and cannot be switched to clopidogrel.
- Patients who are allergic to clopidogrel and cannot be switched to ticagrelor.

Doctors who have a patient in these circumstances may apply to Health Canada's Special Access Programme for continued supply for that patient. The application form is available at [this link](#). If Health Canada approves the request, Lilly will supply the medication at no charge. Please note that Eli Lilly Canada has secured a limited amount of American stock to support existing patients that meet the above criteria in completing a 12-month course of treatment. This supply will only be available until the end of February, 2021.

We recognize the constraint this places on your practice, and we're grateful to you for supporting patients through this change.

® Effient is a registered trademark owned by Eli Lilly and Company; used under license



You and your patients are invited to contact Lilly's Customer Resource Centre at 1-888-545-5972 if you have any questions through this process.

If you have any questions about Lilly or our other medicines, we can be reached at the number above, or through www.LillyPro.ca.

Thank you.

Mike Stone
Vice President, Bio-Medicines, and
Chief Marketing Officer
Eli Lilly Canada, Inc.